These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37502434)

  • 1. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
    Ishikawa T; Terai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Clin Exp Hepatol; 2023 Jun; 9(2):172-178. PubMed ID: 37502434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
    Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
    Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374110
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
    Hatanaka T; Kosone T; Saito N; Takakusagi S; Tojima H; Naganuma A; Takagi H; Uraoka T; Kakizaki S
    JGH Open; 2021 Oct; 5(10):1183-1189. PubMed ID: 34622006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2021 Jun; 7(2):172-177. PubMed ID: 34295984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    Takahashi Y; Seko Y; Yamaguchi K; Takeuchi K; Yano K; Kataoka S; Moriguchi M; Itoh Y
    J Gastroenterol Hepatol; 2023 Oct; 38(10):1743-1749. PubMed ID: 37221601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
    Sugimoto R; Iwasa M; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Front Med (Lausanne); 2023; 10():1073025. PubMed ID: 36824614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
    Morishita A; Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Tani J; Shi T; Himoto T; Tatsuta M; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Ono M; Masaki T
    Hepatol Int; 2023 Jun; 17(3):606-614. PubMed ID: 36583842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD.
    Iwadare T; Kimura T; Kunimoto H; Okumura T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2024; 15():1329294. PubMed ID: 38828415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
    Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
    Clin Exp Hepatol; 2022 Dec; 8(4):278-283. PubMed ID: 36683866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.
    Ono H; Atsukawa M; Tsubota A; Arai T; Suzuki K; Higashi T; Kitamura M; Shioda-Koyano K; Kawano T; Yoshida Y; Okubo T; Hayama K; Itokawa N; Kondo C; Nagao M; Iwabu M; Iwakiri K
    JGH Open; 2024 Apr; 8(4):e13057. PubMed ID: 38572327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study.
    Seko Y; Yamaguchi K; Umemura A; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Moriguchi M; Okanoue T; Itoh Y
    Hepatol Res; 2020 Dec; 50(12):1328-1336. PubMed ID: 32926754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia.
    Katsuyama H; Yanai H; Adachi H; Hakoshima M
    Gastroenterology Res; 2023 Aug; 16(4):240-243. PubMed ID: 37691751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up.
    Ikeda S; Sugihara T; Kihara T; Matsuki Y; Nagahara T; Takata T; Kitao S; Okura T; Yamamoto K; Isomoto H
    Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.
    Ikeda S; Sugihara T; Hoshino Y; Matsuki Y; Nagahara T; Okano JI; Kitao S; Fujioka Y; Yamamoto K; Isomoto H
    Yonago Acta Med; 2020 Aug; 63(3):188-197. PubMed ID: 32884438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver.
    Kang MK; Baek JH; Kweon YO; Tak WY; Jang SY; Lee YR; Hur K; Kim G; Lee HW; Han MH; Choi JH; Park SY; Park JG
    Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34207587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Sep; 63(18):2491-2497. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
    Yamada-Shimizu M; Tamaki N; Kurosaki M; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Ishido S; Nobusawa T; Matsumoto H; Keitoku T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    Intern Med; 2024 May; 63(9):1185-1190. PubMed ID: 37779070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
    Sumida Y; Toyoda H; Yasuda S; Kimoto S; Sakamoto K; Nakade Y; Ito K; Osonoi T; Yoneda M
    J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38777770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
    Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
    JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.